Naradex (Naratriptan Hydrochloride)

Naratriptan Hydrochloride, the active ingredient in Naradex, is a Triptan (5‑HT1B/1D receptor agonist) presented as an oral dosage form for oral use. It is indicated for the acute treatment of migraine attacks in adults. GNH USA supplies Naradex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan Hydrochloride belongs to the triptan class and is used to treat migraine‑related conditions. - Migraine without aura: provides rapid relief of headache pain and associated symptoms. - Migraine with aura: reduces the intensity of headache following aura onset. - Acute migraine attacks: aborts an ongoing migraine episode when taken early in the attack.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Dizziness: transient light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Dry mouth: reduced salivation causing throat discomfort. - Paresthesia: tingling sensations in extremities. - Somnolence: mild drowsiness.

Serious or Rare Side Effects: - Chest pain or tightness: may indicate cardiac ischemia. - Coronary vasospasm: rare constriction of coronary arteries. - Serotonin syndrome: potentially life‑threatening condition when combined with other serotonergic agents. - Severe hypertension: sudden increase in blood pressure. - Allergic reactions: rash, swelling, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythms.

Before prescribing Naradex, clinicians should consider the following precautions: - Cardiovascular assessment: evaluate history of coronary artery disease or uncontrolled hypertension. - Contraindications: avoid in patients with known hypersensitivity to naratriptan or other triptans. - Drug interactions: review concomitant serotonergic medications to reduce serotonin syndrome risk. - Hepatic function: use caution in patients with moderate to severe liver impairment. - Pregnancy and lactation: assess risk‑benefit ratio as safety data are limited. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Naradex may interact with several drug classes. Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Ergot alkaloids (e.g., ergotamine): additive vasoconstriction may precipitate coronary events. - Other triptans: combined use can increase vasospastic complications. Moderate Interactions (Monitor Closely): - SSRIs, SNRIs, and other serotonergic agents: monitor for signs of serotonin excess. - CYP1A2 inhibitors (e.g., fluvoxamine): may increase naratriptan plasma levels. - Antihypertensive agents: monitor blood pressure for additive effects.